Buradasınız

Anasayfa » Content

Foam Skleroterapiye Bağlı Nadir Bir Komplikasyon: Akut Böbrek Hasarı

An Unusual Complication of Foam Sclerotherapy: Acute Kidney Injury

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1003.18

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Sclerotherapy, in which an irritant solution is administered, is a method used to treat venous failure that results in complete venous destruction due to endothelial reaction and fibrosis. In recent years, foam sclerotherapy, in which a sclerosing agent (aethyl sclerole) and air are mixed until they turn into foam and the resultant mixture is injected into noticeable veins directly and into other veins under ultrasonography in doses depending on the diameters of the varices, has been introduced. The drugs or gases used in foam sclerotherapy can cause local or systemic complications. Foam affects vessel endothelial cells and causes severe spasm in the vessel. It has been reported that endothelin-1 levels are high after foam sclerotherapy compared to the initial levels and that neurological complications vary with the endothelin levels. In this report, we present a case of acute kidney injury due to acute tubular necrosis probably caused by endothelin release following foam sclerotherapy.
Bookmark/Search this post with
Abstract (Original Language): 
Skleroterapi; irritan bir solüsyon aracılığıyla vende oluşan endotelyal reaksiyon ve fibrozisle komplet venöz destrüksiyona neden olarak venöz yetmezliğin tedavisinde kullanılan bir yöntemdir. Son yıllarda gündeme gelen foam skleroterapi yöntemindeyse; sklerozan ajan (aethyl sklerol) ve hava köpük halini alıncaya kadar karıştırılır. Meydana gelen karışım belirgin varislerde direkt, diğerlerinde ise ultrasonografi eşliğinde varislerin çapına göre değişen iğnelerle damara verilir. Foam skleroterapide kullanılan ilaç veya gaza bağlı lokal veya nadiren sistemik komplikasyonlar oluşabilir. Foam, damar endotelyal hücrelere etki ederek damarda yoğun bir spazma neden olmaktadır. Foam skleroterapi sonrası endotelin-1 seviyelerinin başlangıca göre yükseldiği ve gelişen nörolojik komplikasyonların endotelin yüksekliğine bağlı olduğu belirtilmektedir. Biz, foam skleroterapi sonrası endotelin salınımı aracığı ile oluşabileceğini düşündüğümüz “akut tübüler nekroza bağlı akut renal hasar” gelişen bir olguyu sunuyoruz.
FULL TEXT (PDF): 
PDF icon arastirmax-foam-skleroterapiye-bagli-nadir-bir-komplikasyon-akut-bobrek-hasari.pdf
  • 3
269
271
  • Turkish

REFERENCES

References: 

1. Heck M, Faulhaber J, Breu FX, Schneider SW: Foam sclerotherapy:
Uses and indications in dermatology and phlebology. Hautarzt
2012; 63(6):493-505
2. Hanisch F, Müler T, Krivokuca M, Winterholler M: Stroke following
variceal sclerotherapy. Eur J Med Res 2004; 9:2823. Frullini A, Barsotti MC, Santoni T, Duranti E, Burchielli S, Di
Stefano R: Significant endothelin release in patients treated with
foam sclerotherapy. Dermatol Surg 2012; 38(5):741-747
4. Nicolaides AN, Allegra C, Bergan J, Bradbury A, Cairols M,
Carpentier P, Comerota A, Delis C, Eklof B, Fassiadis N, Georgiou N,
Geroulakos G, Hoffmann U, Jantet G, Jawien A, Kakkos S, Kalodiki
E, Labropoulos N, Neglen P, Pappas P, Partsch H, Perrin M, Rabe
E, Ramelet AA, Vayssaira M, Ioannidou E, Taft A: Management of
chronic venous disorders of the lover limbs: Guidelines according
to scientific evidence. International Angiology 2008; 27:1-59
5. Jawien A: The influence of environmental factors in chronic venous
insufficiency. Angiology 2003;54 Suppl 1: S19-31
6. Eberhardt RT, Raffetto JD: Chronic venous insufficiency. Circulation
2005; 111;2398-2409
7. Bhogal RH, Moffat CE, Coney P, Nyamekye IK: Can foam
sclerotherapy be used to safely treat bilateral varicose veins?
Phlebology 2012; 27 (1):19-24
8. Asciutto G, Lindblad B: Catheter-directed foam sclerotherapy
treatment of saphenous vein incompetence. Vasa 2012;41(2):120-
124
9. Tessari L, Cavezzi A, Frullini A: Preliminary experience with a new
sclerosing foam in the treatment of varicose veins. Dermatol Surg
2001; 27:58-60
10. Trevisani F, Colantoni A, Gerbes AL, Gülberg V, Sica G, Caraceni
P, De Notariis S, Morselli-Labate AM, Ligabue A, Gasbarrini
G, Bernardi M: Daily profile of plasma endothelin-1 and -3 in
pre-ascitic cirrhosis relationship with arterial pressure and renal
function. J Hepatol 1997; 26; 808-815
11. Neuhofer W, Pittrow D: Role of endothelin and endothelin receptor
antagonists in renal disease. Eur J Clin Invest 2006; 36 Suppl 3:78-
88
12. Loutzenhiser R, Epstein M, Hayashi K, Horton C: Direct
visualization of effects of endothelin on the renal microvasculature.
Am J Physiol 1990; 258: F61-68
13. Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B,
Koomans HA: Effects of endothelin-1 on renal function in humans:
Implications for physiology and pathophysiology. Kidney Int
1994;46:376-381
14. Itoh S, Sasaki T, Ide K, Ishikawa K, Nishikibe M, Yano M: A novel
endothelin ETA receptor antagonist, BQ 485, and its preventive
effects on experimental cerebral vasospasm in dogs. Biochem
Biophys Res Common 1993; 195:969-975
15. Ruschitzka F, Shaw S, Gygi D, Noll G, Barton M, Lüscher TF:
Endothelial dysfunction in acute renal failure: Role of circulating
and tissue endothelin-1. J Am Soc Nephrol 1999; 10(5):953-962
16. Cavezzi A, Parsi K: Complications of foam sclerotherapy.
Phlebology 2012; 27 Suppl 1:46-51

Thank you for copying data from http://www.arastirmax.com